WM Technology, Inc. Q4 & Full Year 2025 Results March 12, 2026 Disclaimer This presentation is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to WM Technology, Inc. ("WM", the "Company", "we", "us", "our") and for no other purpose. References in this presentation to the "10- K" refer to the Annual Report on Form 10-K for the period ended December 31, 2025 filed with the Securities and Exchange Commission (the "SEC"). No ...

2025 Fourth Quarter Conference Call WHEATONPM.COM March 2026 TSX | NYSE | LSE: WPM Cautionary Statements Cautionary Note Regarding Forward-Looking Statements The information contained in this presentation contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of Canadian securities legislation, in particular, but not limited to, the future price of commodities, the absence of control ...

Q4 2025 Supplemental Information Profitably and Sustainably Growing Value March 2026 Safe Harbor Statement Forward Looking Statements Safe Harbor This presentation of VAALCO Energy, Inc. ("Vaalco" or the "Company") includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applica ...

Full-Year 2025 Earnings Presentation March 2026 NYSE: MNR machnr.com Disclaimer and Forward-Looking Statements This presentation is being provided by Mach Natural Resources LP (the "Company" or "Mach") for informational purposes only. No persons have been authorized to make any representations regarding the information contained in this presentation, and if given or made, such representations should not be considered as authorized. None of the Company, its respective affiliates or any of its or their respec ...

Results through Q4 2025 PRESENTATION INVESTOR Peter Hoetzinger, Co CEO & President FORWARD-LOOKING STATEMENTS This presentation may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. Century Casinos, Inc. (together with its subsidiaries, the "Company", "we", "us", "our") may make other written and oral co ...

Financial Data and Key Metrics Changes - For Q4 2025, revenue was $132.7 million, up from $106.8 million in the prior year, driven by acquisitions and a 0.3% reported organic revenue growth [12] - Full year 2025 total revenue reached $463.4 million, a 16.2% increase year-over-year, primarily due to acquisitions and higher organic revenue [13] - Adjusted EBITDA for Q4 was $36.3 million, compared to $33.1 million in the prior year, marking a 9.7% increase [14] - Full year adjusted EBITDA totaled $127.1 million, up 25% from $101.7 million in the previous year [14] - Free cash flow for Q4 was $10.1 million, down from $18.4 million in the prior year, while full year free cash flow was $34.3 million, compared to $37.0 million in 2024 [15][16] Business Line Data and Key Metrics Changes - Reported organic revenue growth for the full year was 1.1%, but if acquisitions were included in 2024, organic revenue growth would have been 4.8% [5][13] - The company focused on reshaping its portfolio to increase exposure to higher growth markets while exiting underperforming brands [6][7] Market Data and Key Metrics Changes - The demand for the company's events remains strong, particularly in the U.S. market, which serves as a key marketplace for both domestic and international participants [9] - The company continues to see solid interest from international exhibitors seeking access to U.S. buyers, presenting opportunities for global customer engagement [9] Company Strategy and Development Direction - The company aims to maintain disciplined execution and build on the strong foundation established across its business in 2026 [10] - Focus areas include organic efficiencies through investments in automation and scalable platforms, as well as selective M&A to strengthen the portfolio [10][11] - The company is actively evaluating strategic options, with no updates to share at this time [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the portfolio and the predictability of earnings, with a positive outlook for 2026 [8][19] - The company expects revenue in the range of $490 million to $495 million and adjusted EBITDA between $137.5 million and $142.5 million for 2026, reflecting approximately 6% revenue and 10% adjusted EBITDA growth year-over-year [19] Other Important Information - The company had $100.9 million in cash as of December 31, 2025, with total liquidity of $210.4 million [18] - A quarterly dividend of $0.015 per share was declared, demonstrating a commitment to returning capital to shareholders [19] Q&A Session Summary Question: Free cash flow conversion for 2026 guidance - Management expects free cash flow to be between $85 million and $90 million, assuming normalized conditions [22][24] Question: Impact of current Middle East situation on travel to trade shows - Management indicated minimal impact, with less than 1% of revenue coming from Middle Eastern exhibitors [26][27] Question: Status of acquisitions and integration - Acquisitions are performing as expected, and integration is on plan [37] Question: Update on Las Vegas Convention Center construction - Construction is completed, and the company expects to cycle past the impacts in 2026 [39] Question: AI initiatives and plans for 2026 - The company is implementing AI agents to improve exhibitor experience and has early signs of success in various business areas [49][50] Question: M&A environment characterization - The M&A environment remains strong, with many opportunities in a fragmented industry [54]

Financial Data and Key Metrics Changes - Fourth quarter net revenues reached RMB 1.14 billion, up 40.3% year-over-year, while total net revenues for the full year grew 44% to RMB 3.96 billion [13] - Gross margin expanded to 31.4% in the fourth quarter, up from 27% a year ago, and for the full year, gross margin increased to 29.9% [13][14] - Non-GAAP operating income doubled to RMB 570 million for the full year, with non-GAAP net income surging to RMB 1.16 billion [14] Business Line Data and Key Metrics Changes - International sales accounted for 76.5% of fourth quarter revenue, indicating a significant shift towards global operations [6] - In the Asia Pacific region, the company captured over 20% of the specialty store channel and increased channel revenue by over 200% [7] Market Data and Key Metrics Changes - Domestic revenue in mainland China grew by over 20% in 2025, driven by stricter customs enforcement reducing the illegal market [9] - The European market is expected to consolidate around established compliant brands, with a positive outlook for 2026 due to new excise taxes favoring compliant operators [26] Company Strategy and Development Direction - The company is focusing on multidimensional global expansion and building a competitive moat in Europe through strategic partnerships and compliance with local regulations [8] - AI integration is a core strategy to enhance operational efficiency and predict consumer preferences, allowing for faster product launches and improved supply chain management [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability and predictability of international business growth for 2026, projecting double-digit growth for the broader industry [19] - The company aims to maintain a strong cash position while selectively deploying capital towards disciplined M&A and strategic investments [21] Other Important Information - The company ended 2025 with total financial assets of RMB 15.73 billion (approximately $2.2 billion), providing financial flexibility for strategic initiatives [15] - Over $500 million has been returned to shareholders through dividends and share repurchases, with plans to continue optimizing capital structure for shareholder returns [20] Q&A Session Summary Question: Expectations for overseas business growth and strategies - Management expects a stable environment for international business in 2026, projecting significant growth faster than the industry average, with a strong pipeline of international markets [19] Question: Update on European operations and outlook for 2026 - European operations have shown resilience despite market contractions, with a positive outlook for 2026 as the industry consolidates around compliant brands [26] Question: Progress of nicotine pouch products and market conditions - Rollouts of modern oral products in Europe have begun, with positive consumer feedback, and the company is focusing on channel expansion for these products [39]

Financial Data and Key Metrics Changes - Revenues for 2025 increased by 3.8% year-over-year to $1.033 billion, up from $995.6 million in 2024 [10][23] - Operating income for 2025 was $45.5 million, a significant improvement from an operating loss of $68.8 million in 2024, positively impacted by an $81.7 million gain from the sale of the property management division [10][24] - Adjusted EBITDA improved to a loss of $14 million in 2025, compared to a loss of $24.1 million in 2024 [10][25] - Net income for 2025 was $15.2 million or $0.17 per diluted share, compared to a net loss of $76.3 million or ($0.91) per diluted share in 2024 [24] Business Line Data and Key Metrics Changes - Revenues from the development marketing division increased by $12.6 million from the prior year, totaling $80.4 million in 2025, up from $67.8 million in 2024 [14][17] - The average price per transaction in 2025 increased to $1.86 million per home sold, compared to $1.67 million in 2024 [15] - The development marketing division has an active project pipeline totaling $25.3 billion in gross transaction value, with $17.5 billion in Florida alone [16][17] Market Data and Key Metrics Changes - The Northeast market led revenue increases, with a rise of $17.5 million or 9.2% from 2024 [18] - In the fourth quarter of 2025, agents sold 282 homes priced over $5 million, representing 5.4% of total transactions, and 1,282 such homes during the year, a 25% increase from 2024 [16] - Cash receipts from existing home sales in January and February 2026 were 11% lower than the same period in 2025 [18] Company Strategy and Development Direction - The company is focused on expanding its footprint in existing markets and entering new high-potential regions, including recent expansions into the French Alps and other luxury destinations [5][6] - Two growth teams have been launched: one focused on expanding within current markets and another on new market expansion [6][7] - The company has reinforced its leadership team to drive growth and innovation, including the appointment of a Chief Strategy Officer and a Chief Technology Officer [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positive momentum and competitive advantage due to a strong balance sheet, which allows for growth in existing and new markets [13][20] - The company anticipates that 2026 will mark the beginning of a new growth phase as investments made in 2025 begin to yield results [11][27] - Management acknowledged ongoing economic pressures, including geopolitical uncertainties and elevated mortgage rates, but remains optimistic about future performance [18] Other Important Information - The company had cash and cash equivalents of approximately $115.5 million at December 31, 2025, with no long-term debt following the redemption of convertible notes [11][20] - The company has made significant investments in market intelligence, technology, and agent resources, including the launch of a new market data report program [9] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session. The call concluded without a detailed Q&A segment [28]

Financial Data and Key Metrics Changes - Revenues for 2025 increased by 3.8% year-over-year to $1.033 billion, up from $995.6 million in 2024 [10][23] - Operating income for 2025 was $45.5 million, a significant improvement from an operating loss of $68.8 million in 2024, positively impacted by an $81.7 million gain from the sale of the property management division [10][24] - Adjusted EBITDA improved to a loss of $14 million in 2025, compared to a loss of $24.1 million in 2024 [10][25] - Net income for 2025 was $15.2 million or $0.17 per diluted share, compared to a net loss of $76.3 million or ($0.91) per diluted share in 2024 [24] Business Line Data and Key Metrics Changes - Revenues from the development marketing division increased by $12.6 million from the prior year, totaling $80.4 million in 2025, up from $67.8 million in 2024 [14][17] - The average price per transaction in 2025 increased to $1.86 million per home sold, compared to $1.67 million in 2024 [15] - The number of homes sold priced over $5 million increased by 25% in 2025, with 1,282 such homes sold [16] Market Data and Key Metrics Changes - The Northeast market led revenue increases, with a rise of $17.5 million or 9.2% from 2024 [17] - Total brokerage cash receipts in January and February 2026 were 12.4% lower than the same period in 2025 [18] Company Strategy and Development Direction - The company is focused on expanding its footprint in existing markets and entering new high-potential regions, including recent expansions into the French Alps and other luxury destinations [5][6] - Two growth teams have been launched to support market expansion and agent recruitment [6][7] - The company has reinforced its leadership team to drive growth and innovation, including new appointments in key strategic roles [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positive momentum and competitive advantage due to a strong balance sheet [13] - The company anticipates that 2026 will mark the beginning of a new growth phase as investments made in 2025 begin to yield results [11][20] - Management acknowledged ongoing economic pressures, including geopolitical uncertainties and elevated mortgage rates, but remains optimistic about future opportunities [18] Other Important Information - The company maintained cash and cash equivalents of approximately $115.5 million at December 31, 2025, with no long-term debt [11][26] - The company has made significant investments in market intelligence, technology, and agent resources to enhance service offerings [9] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session. The call concluded without a detailed Q&A segment [28]

Financial Data and Key Metrics Changes - The company ended 2025 with cash totaling $7.6 million, an increase from $3.7 million as of December 31, 2024 [14] - The net loss for Q4 2025 was $1.6 million, or $0.73 per diluted share, compared to a net loss of $2.8 million, or $3.29 per diluted share for Q4 2024 [18] - For the full year 2025, the net loss was $8 million, or $5.32 per diluted share, down from a net loss of $14.1 million, or $17.45 per share in 2024 [18] Business Line Data and Key Metrics Changes - Research and development expenses for Q4 2025 were $0.3 million, down from $0.8 million in Q4 2024, primarily due to decreased manufacturing and consulting costs [15] - For the full year 2025, R&D expenses were $1.8 million, a significant decrease from $5.4 million in 2024, attributed to lower manufacturing and consulting costs [16] - General and administrative expenses for Q4 2025 were $1.3 million, down from $2 million in Q4 2024, mainly due to reduced compensation and professional fees [16] Market Data and Key Metrics Changes - The company is focusing on the recurrent CDI market, which affects approximately 500,000 patients annually in the U.S., resulting in about 30,000 deaths and a public health cost burden of approximately $5 billion [21] Company Strategy and Development Direction - The company is launching a new clinical trial program for ibezapolstat in patients with recurrent CDI, aiming to shift treatment from two agents to one [9] - The company plans to request FDA approval for ibezapolstat under the Limited Population Pathway for Antibacterial and Antifungal Drugs guidance [10] - The company is pursuing funding opportunities for its phase 3 clinical trial programs and considering alternative financial pathways [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the challenging macroeconomic environment and industry sector while continuing to develop ibezapolstat's competitive profile [13] - The FDA's potential shift to a one-trial requirement for registration is seen as a positive development that could benefit the company's clinical development programs [11] Other Important Information - The company received a new patent for its Pol IIIC inhibitors, extending to December 2039, which covers composition of matter and method of use [11] - The company has approximately $7 million to $8 million left on its equity line of credit, which may support ongoing clinical trials [40] Q&A Session Summary Question: What is the primary endpoint for the recurrent CDI trial and its cost? - The primary endpoint is prevention of recurrence, with an evaluation period of eight weeks, and the trial cost is estimated to be between $4 million and $5 million [27][36] Question: When will the pilot study for recurrent CDI start and conclude? - Enrollment is expected to start in the second half of 2026, with full enrollment anticipated in 12-15 months [37] Question: How many patients are projected for the phase 3 trial for recurrent CDI? - The current projection is between 360 and 400 patients for a single trial in the recurrent CDI indication [42] Question: Is U.S.-based manufacturing a focus for the company? - Yes, the company is in discussions with government agencies regarding U.S.-based manufacturing, which is important for potential funding [46] Question: How real is the FDA's one-trial requirement? - Management is optimistic about the one-trial requirement being formalized, which could change the clinical trial landscape [73]